CCDC157, or Coiled-Coil Domain Containing 157, is a protein that is encoded by the CCDC157 gene in humans. The defining feature of this protein, as indicated by its name, is the presence of a coiled-coil domain-a structural motif that typically consists of two or more alpha-helices wrapped around each other to form a stable, rod-like structure. Proteins with coiled-coil domains are known to participate in a wide array of biological functions due to their propensity to facilitate oligomerization and protein-protein interactions.The exact biological function of CCDC157 is not extensively documented. However, given the general roles of coiled-coil domain-containing proteins, CCDC157 may be involved in processes such as intracellular trafficking, organelle organization, signal transduction, and the stabilization of protein complexes. These domains are particularly prominent in the scaffolding of cytoskeletal structures, vesicle transport, mitotic spindle organization during cell division, and the regulation of gene expression when located in the nucleus.
The cellular localization of CCDC157 could provide clues regarding its specific functions. If CCDC157 is found in the nucleus, it might play a part in chromatin organization or gene regulation. Conversely, a cytoplasmic localization might suggest a role in cytoskeletal arrangement or vesicular pathways.Pathological implications of CCDC157 are not well-defined but could potentially emerge from studies examining gene mutations, expression levels, or disruptions in the normal functioning of the protein. Such studies could link CCDC157 to specific diseases or developmental abnormalities.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin, an mTOR inhibitor, might indirectly affect CCDC157 by modulating cellular growth and autophagy processes, which could influence proteins involved in these pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, can affect various signaling pathways, potentially altering the expression or function of proteins like CCDC157 involved in cellular processes regulated by PI3K. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, by inhibiting p38 MAPK, could indirectly influence CCDC157 function, as p38 MAPK is key in inflammatory responses and stress-induced pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a PI3K inhibitor, may alter CCDC157-related pathways by affecting cellular processes like growth, survival, and metabolism. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059, an inhibitor of MEK, may indirectly modulate CCDC157 activity by influencing the MAPK/ERK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, might affect CCDC157 indirectly by modulating cellular stress responses and apoptosis pathways. | ||||||
LY3214996 | 1951483-29-6 | sc-507299 | 5 mg | $260.00 | ||
LY3214996, an ERK1/2 inhibitor, potentially impacts CCDC157 indirectly by modulating signaling pathways involved in cell proliferation and differentiation. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $56.00 $169.00 | 8 | |
Torin 1, an mTOR inhibitor like Rapamycin, can indirectly affect the function or expression of CCDC157 by altering cellular growth and autophagy pathways. | ||||||
BIX 02189 | 1094614-85-3 | sc-364436 sc-364436A | 5 mg 10 mg | $220.00 $378.00 | 5 | |
BIX 02189, a MEK5 inhibitor, might indirectly influence CCDC157 through pathways involving the ERK5/MAPK7 cascade. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $28.00 $80.00 $412.00 $1860.00 $2962.00 | 5 | |
Selumetinib, a MEK inhibitor, could indirectly affect CCDC157 by modulating the MAPK/ERK pathway, impacting cell growth and differentiation. | ||||||